What are the recommended treatments for COVID-19 at different severity levels?

COVID-19 Treatment Recommendations by Severity Level

For non-severe COVID-19 at high risk of hospitalization, use nirmatrelvir/ritonavir (Paxlovid) as first-line treatment; for severe/critical hospitalized COVID-19, use dexamethasone with consideration of adding baricitinib or IL-6 inhibitors. 1

Non-Severe COVID-19 (Outpatient Management)

High-Risk Patients (Older age, immunocompromised, significant comorbidities)

First-line: Nirmatrelvir/ritonavir (Paxlovid)

• Dosing: 300 mg nirmatrelvir/100 mg ritonavir orally every 12 hours for 5 days 1
• Timing: Must start within 5 days of symptom onset 1
• Renal adjustment: Reduce to 150 mg/100 mg every 12 hours if eGFR 30-59 mL/min 1
• Key benefit: High certainty evidence for important reduction in hospitalization and moderate certainty for mortality benefit 1
• Critical caveat: Ritonavir causes extensive drug-drug interactions—check Liverpool COVID-19 drug interaction tool before prescribing 1

Second-line: Molnupiravir (if nirmatrelvir/ritonavir contraindicated)

• Dosing: 800 mg orally every 12 hours for 5 days 1
• Important warnings:
  • Avoid in pregnancy (perform pregnancy test first), men planning conception within 3 months, and younger adults due to genotoxicity concerns 1
  • Inferior to nirmatrelvir/ritonavir for reducing hospitalization 1
  • Use reliable contraception during treatment and 4 days after (women) or 3 months after (men) 1

Moderate-Risk Patients

Conditional recommendation FOR nirmatrelvir/ritonavir 1

• Same dosing as above
• Smaller absolute benefit than high-risk patients but still important reduction in hospitalization
• Conditional recommendation AGAINST molnupiravir due to safety concerns and smaller benefits 1

Low-Risk Patients

Recommend AGAINST antiviral treatment 1

• Trivial benefits do not justify costs, potential harms, or drug interactions
• Supportive care only

Critical Exclusions for Outpatient Antivirals

• Do NOT use systemic corticosteroids in non-severe COVID-19—may increase 28-day mortality 1
• Do NOT use inhaled corticosteroids or immune therapies in mild-moderate community cases 2

Severe COVID-19 (Hospitalized, SpO2 ≤94% on room air)

Core Treatment Algorithm

Step 1: Dexamethasone (Foundation therapy)

• Dosing: 6 mg daily (or equivalent corticosteroid) 3
• Duration: Up to 10 days or until discharge
• Evidence: Decreases mortality in severe/critical COVID-19 3

Step 2: Add Baricitinib (JAK inhibitor)

• Indication: Severe COVID-19 on high-flow oxygen or non-invasive ventilation 4
• Dosing: 4 mg daily (adjust for renal function) for up to 14 days or discharge 4
• Recommendation: Use baricitinib WITH corticosteroids (conditional recommendation, moderate certainty) 4
• Greatest benefit: Patients on high-flow oxygen/non-invasive ventilation at baseline 4

Alternative if corticosteroid contraindicated:

• Baricitinib 4 mg daily + remdesivir (conditional recommendation, low certainty) 4
• Note: Benefits uncertain for mechanically ventilated patients 4

Step 3: Consider IL-6 Inhibitors (Tocilizumab)

• For extensive lung disease with elevated IL-6 5
• Contraindicated in active tuberculosis 5

Respiratory Support Progression

1. Supplemental oxygen for SpO2 <90%
2. High-flow nasal cannula or non-invasive ventilation for persistent hypoxemia 6
3. Intubation and invasive ventilation for severe hypoxemia/high respiratory rate 3

Thromboprophylaxis

• Standard: Prophylactic anticoagulation for all hospitalized patients 3
• Intensified prophylaxis: Consider if obesity, known thrombophilia, ICU admission, or elevated D-dimers 3

Critical COVID-19 (ICU, Mechanical Ventilation, ARDS)

Treatment Combination

• Dexamethasone 20 mg daily for 5 days, then 10 mg daily for 5 days (initiate within 24 hours of ARDS diagnosis) 5
• Consider adding tocilizumab for ARDS 5
• Remdesivir: 200 mg IV loading dose, then 100 mg daily for 2-10 days 5, 7
  • Note: Role controversial and evidence mixed 8

Key Clinical Pitfalls to Avoid

1. Timing failure: Antivirals ineffective if started >5 days after symptom onset 1, 2
2. Drug interaction disasters: Always check ritonavir interactions before prescribing nirmatrelvir/ritonavir 1
3. Corticosteroid misuse: Never use in non-severe outpatient COVID-19 1
4. Molnupiravir in pregnancy: Absolute contraindication due to genotoxicity 1
5. Baricitinib monotherapy: Should be combined with corticosteroids in severe disease, not used alone 4
6. Ignoring thromboprophylaxis: Essential in all hospitalized patients 3

Special Populations

Pregnant patients: Nirmatrelvir/ritonavir is an option despite uncertainty; no serious adverse reactions reported in WHO Vigibase 1

Renal impairment: Dose-reduce nirmatrelvir/ritonavir; use with caution in severe impairment 1

Immunocompromised: Prioritize for antiviral therapy given high risk 2